TECH High-end Type II diabetes drug launched

TECH

High-end Type II diabetes drug launched

China Daily

20:37, April 08, 2020

Qingdao Baheal Pharmaceutical Co Ltd launches "Nida", an extended-release tablet containing metformin for type-2 diabetes management on April 7, 2020. (Photo: Official website of Baheal Pharmaceutical Co Ltd)

Qingdao Baheal Pharmaceutical Co Ltd, a holding subsidiary of Chinese pharmaceutical giant Baheal Pharmaceutical Group, announced on Tuesday that its high-end generic medicine, "Nida", an extended-release tablet containing metformin for type-2 diabetes management, was officially launched in China.

According to the International Diabetes Federation, China currently has more than 116.4 million diabetic patients, and most of them suffer from type-2 diabetes.

Patients with a doctor's prescription now can buy the drug from offline pharmacies, hospitals, and the company's online platforms.

The company said the drug uses an advanced controlled-release mechanism to release the metformin over a controlled period to ensure stable drug effect, so that patients only need to take one dose a day, which can help avoid gastrointestinal adverse reactions and missed medication doses.

The company will proactively communicate with regulators to ensure the drug will be included into the country's drug reimbursement list as soon as possible to reduce patients' financial burden, although the drug is priced quite modestly, it said.

Chinese authorities reviewed the generic under fast track and approved its market launch in January.

The drug also received market approval from the US Food and Drug Administration in late 2018 and was officially launched in the US in early 2019.

Related Stories

Terms of Service & Privacy Policy

We have updated our privacy policy to comply with the latest laws and regulations. The updated policy explains the mechanism of how we collect and treat your personal data. You can learn more about the rights you have by reading our terms of service. Please read them carefully. By clicking AGREE, you indicate that you have read and agreed to our privacy policies

Agree and continue